Intimation for commissioning 100TPD Sorbitol Unit at our existing unit in Hubli, Karnataka:
Posts in category Value Pickr
Praveen’s Portfolio (17-02-2024)
Hi Hemanth.
Not sure about TAAL.
Coming to axiscades: Axiscades is well diversified and does more value added work. What Moldtek Tech does is plain Vanilla work in Just stuructural Eng (CIvil and Construction). The Mechanical Eng Division of Moldtek is relatively better (IMO) but still a long way to go. So, overall I don’t think Moldtek is as good as Axiscades but the growth rates have been good in recent past and the management indication that they are closing in on an acquisition (mentioned in Q2 concall) is a step in right direction. In addition to this, seasoned management (proven track record in Moldtech pack) and good addressable (global) market with Cost advantage (working out of India) forms my thesis.
As per Q3 concall managment commentary, they were asked by clients to serve them in Press tool
The co is moving into Press Tool, Dies, Wiring Harnesses etc. So, they have onboarded some employees to increase the capabilities. This would be the thing to watch out for in near future
I’ll check TAAL and keep an eye on axiscades as well.
Thanks
Praveen
Wockhardt: an NiCE story (17-02-2024)
Currently sales, net profit are on the -ve side of the axis.
Even if they get success with all the mentioned trials and go in production.
It can increase sell /revenue. But will it make enough profit as much as retail investors are expecting is yet to come out.
So far they have run the business badly.
Dilution , promoter sell offs in last 3 quarters.
Deliverables: Their team is going to deliver the solution for the Pneumonia problem.
Marketing and sales deliverable is yet to be proven.
We need to watch out the business post all the approvals.
Risk is huge here even after the success of trials.
Based on technical deliverables people are taking huge position.
Sales validation is yet to happen.
Rohit’s Portfolio : Requesting Feedback (17-02-2024)
How you decide the percentage of the any specific stock?
No of stocks or amount or some other parameter?
Mrs Bectors Food Specialities: Can it beat the industry? (17-02-2024)
Which QSR are customer of bector food & how much revenue they generate from QSR segment?
Rohit’s Portfolio : Requesting Feedback (17-02-2024)
Trying to stick to my habit of journalling my investing journey and try and develop a strong investing process. Used the recent pullback to exit positions with strong headwinds – Globus Spirit, Deepak Fert, SBCL, Mayur Uniquoters and enter new positions with strong tailwinds – IWEL, Jindal Stainless, STAR and Garware HiTech.
Learning is to not get married to “hopium” for stocks like Deepak Fert/Globus Spirit and absorb a loss. Am almost at break-even now with the profits in my new positions bought during the dip.
Stocks I am looking for an entry point/want to add more – KDDL, Jindal Stainless, Gujarat Fluorochem, Shilchar Technology and Vaibhav Global
Stocks I am tracking for a reversal – Laurus Labs, Jubilant Ingrevia, Cosmo First – kick-in of operating leverage in the first two like Aarti Industries
Stock I am looking to exit – IEX
Current portfolio stands as below (PF up +5% from the last update 22 days ago):
| Symbol | Sector | P&L chg. | % Allocation |
|---|---|---|---|
| NEULANDLAB | Pharma | 159.74% | 7.8% |
| TATAPOWER | Energy | 69.03% | 6.8% |
| NCC | Infrastructure | 42.46% | 6.5% |
| SWSOLAR | Energy | 52.76% | 6.2% |
| POLYCAB | Infrastructure | 119.80% | 6.1% |
| NH | Pharma | 69.86% | 4.9% |
| AARTIIND | Speciality Chemicals | 20.34% | 4.9% |
| RACLGEAR | Auto | 61.58% | 4.8% |
| ICICIBANK | Financials | 7.71% | 4.6% |
| GRAVITA | Others | 43.25% | 4.2% |
| TIPSINDLTD | Consumption | 32.31% | 3.6% |
| RELIANCE | Consumption | 25.28% | 3.2% |
| PRAKASH | Metals | 11.70% | 3.1% |
| APLAPOLLO | Infrastructure | 10.51% | 2.9% |
| KPITTECH | IT | 128.40% | 2.9% |
| MASTEK | IT | 15.09% | 2.7% |
| SOUTHBANK | Financials | -7.56% | 2.6% |
| EQUITASBNK | Financials | -2.12% | 2.2% |
| IEX | Energy | -6.12% | 2.1% |
| JBCHEPHARM | Pharma | 20.67% | 2.0% |
| PRICOLLTD | Auto | 22.83% | 1.9% |
| GRWRHITECH | Auto | 8.73% | 1.7% |
| INTELLECT | IT | 11.87% | 1.6% |
| SHILCHTECH | Energy | 8.03% | 1.6% |
| STAR | Pharma | 3.00% | 1.5% |
| TANLA | IT | -12.76% | 1.3% |
| FLUOROCHEM | Speciality Chemicals | -1.58% | 1.3% |
| IWEL | Energy | 7.85% | 1.2% |
| VAIBHAVGBL | Consumption | 1.87% | 1.2% |
| JSL | Metals | 1.01% | 0.7% |
| LAURUSLABS | Pharma | -4.76% | 0.6% |
| SGBSEP27-GB | Gold | 63.18% | 0.6% |
| PHARMABEES | Pharma | 0.58% | 0.4% |
| JUBLINGREA | Speciality Chemicals | 6.70% | 0.3% |
| COSMOFIRST | Speciality Chemicals | -3.79% | 0.2% |
Windlas Biotech – Pure play CDMO currently at ~1.1x sales (17-02-2024)
Windlas Biotech Q3 FY24 Concall notes:
- Very upbeat commentary by management.
- Injectible facility to be commerialized by end of FY24 and scaleup in FY25.
- Current quarterly revs at 160 crs. Potential upto 600-750 Crs/quarter after all capex is commercialized.
- Growth is good in trade generics and CDMO business.
- CDMO business is picking pace. No lumpy revenue here.
- Want to grow quarter on quarter (QoQ). Shows consistency in growth.
- Growing faster than Pharma industry.
- Based in Dehradun. Focus on North Indian markets.
- Exports are currently slow.
- Positive on all 3 verticals- CDMO, Trade generics & exports.
- Focus on sustainable and efficient operations.
- Higher employee expenses, lowering of margins due to ESOP scheme.
- Schedule M impact is to seen across CDMO players, as non-compliant facilities will be under crackdown.
NGL Fine-Chem (Animal Health + Human Health + Vet Formulations) (17-02-2024)
Agree. I feel true test of a company is when things are bad…the whole industry is in bad shape and if we compare performance of NGL to peers like Sequent, Lasa one can clearly see the difference. The management commentary has improved now and the capex plans are back in action now.
The market has been smart and patient on good cos.
Ayush
Disc: continue to be invested in family and client acs
Tips Industries Limited – Ready to RACE ahead! (17-02-2024)
Stance: Invested, Looking to add more in case of dips
Don’t think there is any news on this behind the recent rally.
I guess this is what the bull market does. However, the business continues to show strong fundamentals.
In fact, PE ratio of global music labels are also >40 presently.
Warner Music – ~40 PE
Universal music – ~42 PE
Generally, there is a premium for Indian companies; Hence, the valuation of 50 PE for Tips can be justified, because they show strong promise of 30% growth.
However, nothing can be said about valuations in bull markets. Given the business model is superb, I may add this whenever there is a drop in price.